Fiera Capital Corp Grows Stock Position in Option Care Health, Inc. (NASDAQ:OPCH)

Fiera Capital Corp increased its holdings in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 3.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 650,450 shares of the company's stock after acquiring an additional 21,900 shares during the period. Fiera Capital Corp owned about 0.40% of Option Care Health worth $22,733,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Quadrant Capital Group LLC grew its holdings in Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock valued at $40,000 after purchasing an additional 1,099 shares during the period. Public Employees Retirement System of Ohio grew its holdings in Option Care Health by 21.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after purchasing an additional 332 shares during the period. Johnson Financial Group Inc. bought a new position in Option Care Health during the fourth quarter valued at $47,000. Bessemer Group Inc. grew its holdings in Option Care Health by 62.3% during the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after purchasing an additional 599 shares during the period. Finally, Wealthquest Corp bought a new position in Option Care Health during the first quarter valued at $66,000. 98.05% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. UBS Group raised Option Care Health from a "neutral" rating to a "buy" rating and raised their price target for the stock from $38.00 to $40.00 in a report on Wednesday, April 30th. Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a report on Thursday. Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. Finally, JMP Securities lifted their price objective on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research note on Thursday. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $35.75.

Option Care Health Price Performance

OPCH stock traded down $1.09 during mid-day trading on Friday, hitting $28.26. 1,842,798 shares of the stock were exchanged, compared to its average volume of 1,424,414. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.52 and a quick ratio of 1.02. The business has a fifty day moving average price of $31.04 and a 200 day moving average price of $31.96. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $35.53. The stock has a market capitalization of $4.59 billion, a price-to-earnings ratio of 22.61, a PEG ratio of 1.86 and a beta of 0.79.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.01. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.35 billion. Option Care Health had a return on equity of 17.53% and a net margin of 3.93%. The company's revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 earnings per share. On average, sell-side analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current year.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.